SMi presents the 13th annual industry leading conference: Cold Chain Distribution

SMi Group10 - 11 December 2018, London, UK.
The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry.

The two-day event will also look at various developments within the industry, guiding companies on how best to ensure costs are kept low, and quality remains high, whilst simultaneously staying compliant to global regulations.

This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations and issues in the field of temperature-controlled distribution.

Chairs for 2018

  • Bob Hayes, Director, SeerPharma (UK)
  • Tony Wright, CEO, Exelsius

Featured Speakers

  • Bob Hayes, Director, SeerPharma (UK)
  • Stephen Mitchell, Quality Lead Logistics Partnerships, GSK
  • GianneOlaes-Dénis, Supply Chain Quality Manager, SanofiGenzymeEurope
  • Stefan Braun, Managing Director, SmartCAE
  • GianpieroLorusso, Director, Supply Operations and GS, Merck
  • Francicso Rizzuto, Cargo Specialist, Manager for Europe, IATA
  • Marco Gaudesi, Pharmacist - GDP and Cold Chain Referent, MSF
  • Henk Mulder, Head, Digital Cargo, IATA

Key Highlights

  • Evaluate the current GDP guidelines, with reference to the recently published PQG/ECA guide and discover the implications for everyday practice
  • Explore the overwhelming digitalisation of the supply chain and identify the subsequent security issues involved
  • Discover the temperature-controlled logistic solutions to best optimize your supply chain
  • Discuss the technical agreements within the supply chain and find out what questions you should be asking
  • Identify the challenges for the supply chain within emerging markets and discover the best solutions for optimization of your process

View the full agenda online: www.coldchain-distribution.com

  • Register by 29th June and save £400
  • Register by 28th September and save £300
  • Register by 31st October and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...